Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (0) | Back to Search
Translational Model to Predict Pulmonary Pharmacokinetics and Efficacy in Man for Inhaled Bronchodilators
- At: 2017 FIP Congress in Stockholm (Sweden)
- Type: Poster
- By: HENDRICKX, Adriaan (AstraZeneca, DMPK, Mölndal, Sweden)
- Co-author(s): Adriaan Hendrickx: RIA DMPK, AstraZeneca, Mölndal, Sweden
Eva Lamm Bergström: RIA DMPK, AstraZeneca, Mölndal, Sweden
David L. I. Janzén: CVMD DMPK, AstraZeneca, Mölndal, Sweden
Markus Fridén: RIA DMPK, AstraZeneca, Mölndal, Sweden
Ulf Eriksson: RIA QCP, AstraZeneca, Mölndal, Sweden
Ken Grime: RIA DMPK, AstraZeneca, Mölndal, Sweden
Douglas Ferguson: Oncology DMPK, AstraZeneca, Mölndal, Sweden
Inhaled drug therapy is typically used for targeting the lung whilst minimizing systemic exposure in order to improve the benefit/risk margin for treatments of respiratory disease.
AimsThe aim of current study was to develop a translational modelling framework for capturing both lung and systemic PK and efficacy after pulmonary delivery.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.
Last update 4 October 2019